Cargando…
Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors
Autores principales: | Oosting, S.F., van der Veldt, A.A.M., Fehrmann, R.S.N., Bhattacharya, A., van Binnendijk, R.S., GeurtsvanKessel, C.H., Dingemans, A.-M.C., Smit, E.F., Hiltermann, T.J.N., den Hartog, G., Jalving, M., Westphal, T.T., de Wilt, F., Ernst, S.M., Boerma, A., van Zijl, L., Rimmelzwaan, G.F., Kvistborg, P., van Els, C.A.C.M., Rots, N.Y., van Baarle, D., Haanen, J.B.A.G., de Vries, E.G.E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284446/ https://www.ncbi.nlm.nih.gov/pubmed/37450950 http://dx.doi.org/10.1016/j.esmoop.2023.101599 |
Ejemplares similares
-
One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment
por: van der Veldt, A.A.M., et al.
Publicado: (2023) -
LBA8 Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors
por: Oosting, S., et al.
Publicado: (2021) -
Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
por: Oosting, Sjoukje F, et al.
Publicado: (2022) -
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
por: Oosting, Sjoukje F, et al.
Publicado: (2021) -
Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response
por: Hooiveld-Noeken, J.S., et al.
Publicado: (2019)